Viridian Therapeutics

IgG1 monoclonal antibody
#Autoimmune disease #Phase I trial #Therapeutic Antibodies #Viridian Therapeutics

FcRn inhibitor demonstrates sustained IgG reduction in Phase I trial

Viridian Therapeutics has announced positive Phase I trial results for VRDN-008, a half-life extended bifunctional FcRn inhibitor licensed from Paragon Therapeutics.  In the trial, VRDN-008 demonstrated a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile with the potential to be dosed every eight weeks.   VRDN-008… Read More

#News